The combined use of aspirin and a high-dose proton pump inhibitor (PPI) appears to offer protection against the development of esophageal cancer in high-risk individuals, according to new findings presented at the 2018 American Society of Clinical Oncology Annual Meeting (abstract LBA4008). This strategy reduced the risk of developing high-grade dysplasia or progression to malignancy, and delayed death from any cause in people with Barrett esophagus.
http://www.cancernetwork.com/gastrointestinal-cancer/high-dose-ppi-plus-aspirin-reduced-esophageal-cancer-risk
High-Dose PPI Plus Aspirin Reduced Esophageal Cancer Risk